Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
Titel:
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
Auteur:
Toledo-Romaní, María Eugenia García-Carmenate, Mayra Valenzuela-Silva, Carmen Baldoquín-Rodríguez, Waldemar Martínez-Pérez, Marisel Rodríguez-González, Meiby Paredes-Moreno, Beatriz Mendoza-Hernández, Ivis González-Mujica Romero, Raúl Samón-Tabio, Oscar Velazco-Villares, Pablo Bacallao-Castillo, Juan Pablo Licea-Martín, Ernesto Rodríguez-Ortega, Misladys Herrera-Marrero, Nuris Caballero-González, Esperanza Egües-Torres, Liudmila Duartes-González, Reinaldo García-Blanco, Serguey Pérez-Cabrera, Suzette Huete-Ferreira, Santos Idalmis-Cisnero, Kirenia Fonte-Galindo, Omayda Meliá-Pérez, Dania Rojas-Remedios, Ivonne Doroud, Delaram Gouya, Mohammad Mehdi Biglari, Alireza Fernández-Castillo, Sonsire Climent-Ruiz, Yanet Valdes-Balbín, Yury García-Rivera, Dagmar Van der Stuyft, Patrick Verez-Bencomo, Vicente